Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-07-01

FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)

View source ↗

Summary

The FDA approved a supplemental application from Padagis Israel Pharmaceuticals Ltd for a fixed-dose combination tablet of alogliptin benzoate and pioglitazone …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alogliptin benzoate (alogliptin benzoate)
  • Pioglitazone hydrochloride (Pioglitazone hydrochloride)

Snippet

SUPPL AP for ALOGLIPTIN AND PIOGLITAZONE (ALOGLIPTIN BENZOATE AND PIOGLITAZONE HYDROCHLORIDE)